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A B S T R A C T
Purpose: We investigated the usefulness of four-dimensional computed tomography (4DCT) performed
before stereotactic body radiation therapy (SBRT) in determining the internal margins for peripheral lung
tumors.
Methods and Materials: The amplitude of the movement of a ﬁducial marker near a lung tumor mea-
sured using the maximum intensity projection (MIP) method in 4DCT imaging was acquired before the
SBRT (AmpCT) and compared with the mean amplitude of the marker movement during SBRT (Ampmean)
andwith themaximum amplitude of themarker movement during SBRT (Ampmax) using a real-time tumor-
tracking radiotherapy (RTRT) system with 22 patients.
Results: There were no signiﬁcant differences between the means of the Ampmean and the means of the
AmpCT in all directions (LR, P = 0.45; CC, P = 0.80; AP, P = 0.65). The means of the Ampmax were signiﬁ-
cantly larger than the means of the AmpCT in all directions (LR, P < 0.01; CC, P = 0.03; AP, P < 0.01). In the
lower lobe, the mean difference of the AmpCT from the mean of the Ampmax was 5.7 ± 8.0 mm,
12.5 ± 16.7 mm, and 6.8 ± 8.5 mm in the LR, CC, and AP directions, respectively.
Conclusions: Acquiring 4DCT MIP images before the SBRT treatment is useful to establish the mean am-
plitude for a patient during SBRT but it underestimates themaximum amplitude during actual SBRT. Caution
must be paid to determine the margin with the 4DCT especially for tumors at the lower lobe where it is
of the potentially greatest beneﬁt.
© 2016 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Stereotactic body radiation therapy (SBRT) is widely used in the
therapy of localized lung malignancies with patients where the ma-
lignancy is inoperable or where patients refuse to undergo surgical
resection [1–3]. It is important to reduce uncertainties in the target
delineation and localization, and thereby limit the doses to the sur-
rounding normal tissue [4–6].
Four-dimensional computed tomography (4DCT) has beenwidely
used to estimate the internal motion of lung cancers in SBRT.
Underberg et al. have shown that 4DCT is useful to determine the
internal target volume (ITV) in stereotactic body radiation therapy
(SBRT) for stage I lung cancer [7]. Using 4DCT, Liu et al. have shown
that the principal component of the tumormotionwas in the cranial-
caudal direction (CC), with only 10.8% of tumors moving >1.0 cm
based on the data of 4DCT [8].
The accuracy of the ITV determination based on 4DCT has been
compared with other imaging modalities. Cai et al. found that ITVs
based on 4DCT were comparatively smaller than those based on
dynamicmagnetic resonance imaging (MRI) in both phantom studies
and lung tumor patient studies [9]. Purdie et al. have shown that
tumor motion of the planning 4DCT scan did not match that of
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cone-beam CT on the treatment unit at the start of treatment in 2
of 12 patients [10]. They suggested that ITV based on 4DCT could
underestimate the tumor motion and not be suitable for patients
receiving SBRT. However, there is little information about the ac-
curacy of the motion estimated from 4DCT in comparison with the
actual internal motion of tumors during SBRT.
The internal motion of tumors has been shown to vary
in the same patient by analysis of internal ﬁducial marker
movements near the tumor using a real-time tumor-tracking ra-
diotherapy (RTRT) system [11]. The purpose of this study is to
evaluate the accuracy of the amplitude of internal ﬁducial
markers in the lung by comparing 4DCT data with RTRT log data
obtained during SBRT in the same patient. We have not com-
pared displacement of the tumor location between treatments,
which would be relevant to the so called ‘inter-fractional motion’.
We have compared the amplitude of the tumor motion during the
treatment, which is more relevant to the so called ‘intra-fractional
motion’.
Methods and materials
Patients
We obtained approval from the research ethics committee of Hok-
kaido University Hospital for this retrospective study (No. 012-
0395). FromMay 2011 to October 2013, 22 patients with peripheral
lung tumors, who underwent 4DCT and SBRT with a RTRT system,
were included in this study. The median age was 77.5 years (range
63–89). Tumor locations were: 11 upper-middle lobes and 11 lower
lobes (Table S1). As previously described, in a RTRT system, the three-
dimensional (3D) coordinates of a ﬁducial marker which has been
implanted near the lung tumor were recorded every 0.033 seconds
during the SBRT using two sets of ﬂuoroscopes [12]. The outcome
of the SBRT using RTRT has been reported elsewhere [13]. In our
institution, we used RTRT for the lung SBRT using the RTRT system.
The RTRT is basically a gated radiotherapy where the therapeutic
beam is delivered only when the internal ﬁducial marker near the
tumor is within a ±2-mm of the planned position at the end of ex-
piration. This is the reason why we used breath-hold CT images
acquired at the end of expiration for the determination of CTV and
for dose calculations. Five mm was added to the CTV to make the
PTV. The 4DCT image was used for research purposes in this study.
The prescription was 40 Gy in 4 fractions to the 95% of PTV in
principle.
Measurement of amplitudes using 4DCT
Fiducialmarkerswithadiameter of 2mmwere implanted through
endoscopy before the 4DCT. For each lung tumor, 3–4markerswere
implanted near the tumor. No training or visualmonitoring of breath
was used during the 4DCT and RTRT. Patients were breathing freely
andnaturally throughout the4DCTandSBRTprocedures in this study.
Themarker nearest the tumor center is used for the RTRT. The 4DCT
scanwas performed on a 16-slice CT scanner (Optima CT580W; GE
Healthcare, Waukesha, WI) within one week before the SBRT, with
transaxial images acquired during free breathing in the cine mode.
The scan parameters were: 1.0 s gantry rotation, 0.5 s cine interval,
20 mmbeam collimation, and 2.5-mm slice thickness. The datasets
at each table position were acquired for at least the duration of one
respiratory cycle of the patient. During the CT scan, the respiratory
signals of each patientwere recorded andmonitored using a Varian
Real-time Position Management (RPM) system (Varian Medical
Systems, Palo Alto, CA): a box with two infrared reﬂective markers
was placed on the upper abdomen of the patient and itsmovement
was captured by an infrared camera. The raw 4DCT images and the
corresponding respiratory signal data were transferred to an Ad-
vantageWorkstation 4.5 (GE Healthcare,Waukesha,WI) to sort the
4DCT images into 10 respiratory phase-based bins of 3DCT images.
Maximum intensity projection (MIP) imageswere automatically gen-
erated from all 10 phase-based bins of the 3DCT images using the
Advantage 4D software (GE Healthcare, Waukesha, WI).
We used the MIP images from the 4DCT (4DCTMIP) for the mea-
surements of the amplitude of the ﬁducial marker that was tracked
by the RTRT system during the SBRT. The window width was set
to 2000 HU and the window level as 150 HU, and deﬁned a high-
density area over 1000 HU as the trajectory of the marker. We
selected areas of more than 1000 HU as the trajectory of the marker
to distinguish metallic ﬁducial markers from bone or calciﬁcation.
The amplitude of the marker measured with the 4DCT MIP (AmpCT)
was deﬁned as the maximum coordinates minus the minimum co-
ordinates in the left-right (LR), cranial-caudal (CC), and anterior-
posterior (AP) direction coordinates, respectively (Fig. 1). The 3D
scalar amplitude (3DSA) was deﬁned as the AmpCT distance in 3D
coordinates and calculated as DSA = (LR2 + CC2 + AP2)1/2.
Measurement of amplitudes during SBRT using RTRT log data
In the RTRT system, log ﬁles are created continuously during the
delivery of the therapeutic beam for each port unless there is a
a b
Figure 1. a. A maximum intensity projection (MIP) image in the axial plane generated from all 10 phase-based bins of the 3DCT images. The amplitude of the marker mea-
sured with the MIP (AmpCT) was deﬁned as the maximumminus the minimum coordinates in the left-right (LR) and anterior-posterior (AP) directions. b. Another MIP image
in the sagittal plane generated by the same method in the same patient as in (a). The amplitudes of the marker measured with the MIP (AmpCT) in the left-right (LR) and
cranio-caudal (CC) directions are shown.
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baseline shift or recognition of the marker is insuﬃcient; in such
situations, tracking of the marker stopped and the recording of the
log ﬁle is discontinued. A continuous recording is termed as one
‘session’ here and thus each session is recorded in one log ﬁle
(Fig. 2a).
Wemeasured several types of amplitudes for each patient in this
study in the LR, CC, and AP directions: (1) session amplitude, the
maximum amplitude in each session; (2) the maximum ampli-
tude of the day, the maximum session amplitude on the day; (3)
the mean amplitude of the day, the mean of session amplitudes of
the day; (4) the maximum amplitude of the patient during SBRT
(Ampmax), the mean of the maximum amplitudes of one day for the
whole of the treatment; (5) themean amplitude of the patient during
SBRT (Ampmean), the average of the mean amplitudes of the day
during the whole of the treatment (Fig. 2b).
Statistical analysis
The JMP 9 (SAS, Cary, NC) software was used for the statistical
analysis. The AmpCT was compared with the mean of the Ampmean
and Ampmax using the Wilcoxon test. The mean difference of the
AmpCT from the mean of the Ampmean and Ampmax was compared
for the upper-middle and the lower lobes also using the Wilcoxon
test. The statistical relationships between several clinical charac-
teristics and the difference in the AmpCT versus the Ampmean and the
Ampmax were investigated using analysis of variance (ANOVA). The
restricted maximum likelihood (REML) method in linear random
effects model was used to estimate the variance components. As the
clinical characteristics in the analysis, the age, the forced expira-
tory volume in 1 second (FEV1.0), lobe, and the 3DSA were used.
In clinical practice, emphysematous and ﬁbrotic changes in lung
tissue are more common in old age. Also FEV1.0 is often changed
in the diseased lung tissue. Therefore, we have included these pa-
rameters in the analysis. For each factor, the median value was used
to divide the whole of the obtained data into two groups: ages 77
or younger vs. 78 or older, FEV1.0 <1.8 L vs. ≥1.8 L or larger, lobe
upper-middle vs. lower and 3DSA <10mm vs. ≥10mm or larger. The
means of the differences in the amplitudes were compared between
groups using the Wilcoxon test. A P value < 0.05 was considered to
show statistical signiﬁcance.
Results
The mean period between the dates of the 4DCT scan and the
start of the SBRT was 5.6 days (range 3–6). The duration for acqui-
sition of 4DCT images ranged from 87.8 to 139.5 seconds (mean
104.6). In 96 treatments with the 22 patients, the length of the log-
data of the RTRT system for one treatment was from 395 to 1924.3
seconds (mean 1025.5). The duration of the SBRTwas about 10 times
longer than the 4DCT. The average length of session of RTRT log data
was 92.4 seconds (range: 49.6–174.2). There were 11.3 sessions per
fraction of SBRT.
Measurement of amplitudes using 4DCT
Themean of the AmpCT in the 22 patients was 3.6 ± 1.3mm (range
1.9–6.4), 9.4 ± 8.1 mm (1.9–36.1), and 5.5 ± 1.9 mm (3.4–10.4) in the
LR, CC, and AP directions, respectively. Themedian 3DSAwas 9.8mm
(range 4.6–37.7) (Tables S1 and S2).
Analysis based on the mean amplitude of each patient during SBRT
The mean of the Ampmean was 4.2 ± 2.8 mm (0.9–13),
11.4 ± 11.6 mm (1.1–38.0), and 5.7 ± 3.6 mm (1.5–15.7) in the LR, CC,
and AP directions, respectively (Table S2). There were no signiﬁ-
cant differences between the mean of the Ampmean and the mean
of the AmpCT in any direction (LR, P = 0.45; CC, P = 0.80; and AP,
P = 0.65) (Fig. 3a).
In the upper-middle lobe, the mean difference from the ampli-
tude measured with the 4DCT to the mean of the Ampmean in the
22 patients was −0.2 ± 0.8 mm, −1.2 ± 2.7 mm, and −0.9 ± 1.1 mm in
the LR, CC, and AP directions, respectively. In the lower lobe, it was
1.5 ± 3.5 mm, 5.2 ± 11.7 mm, and 1.2 ± 3.8 mm in the LR, CC, and AP
directions, respectively. There were no statistically signiﬁcant dif-
ferences between the differences in the lower lobe and in the upper-
middle lobe in any of the directions (LR, P = 0.15; CC, P = 0.19; and
AP, P = 0.26).
Analysis based on the maximum amplitude of a patient during SBRT
The mean of the Ampmax of all patients was 7.0 ± 6.0 mm (1.7–
28.8), 15.9 ± 16.4 mm (2.0–52.3), and 9.5 ± 7.5 mm (2.4–34.8) in the
LR, CC, and AP directions, respectively (Table S2). The mean of the
Ampmax was statistically signiﬁcantly larger than the AmpCT in all
three directions (LR, P < 0.01; CC, P = 0.03; and AP, P < 0.01) (Fig. 3b).
In the upper-middle lobe, themean difference between the AmpCT
and the mean of the Ampmax was 1.3 ± 1.1 mm, 0.6 ± 3.1 mm, and
1.1 ± 1.7 mm in the LR, CC, and AP directions. In the lower lobe, it
was 5.7 ± 8.0 mm, 12.5 ± 16.7 mm, and 6.8 ± 8.5 mm in the LR, CC,
and AP directions. The differences in the lower lobe were larger than
those in the upper-middle lobe in the CC and AP directions (LR,
P = 0.15; CC, P < 0.05; and AP, P = 0.21) (Fig. 4). Figure 5 illustrates
the position of the markers and the differences between the means
of the Ampmax and AmpCT.
The mean and standard deviations of the difference between the
AmpCT and the Ampmax for the selected clinical characteristics (age,
FEV1.0, lobe, and 3DSA) are shown in Table 1. The difference was
signiﬁcantly larger in the lower lobe than in the upper-middle lobe
in the CC (Upper-middle 0.6 ± 3.1, Lower 12.5 ± 16.7, P < 0.05). The
difference was also larger for those with 3DSA 10mm or larger than
Figure 2. a. Deﬁnition of the amplitude of the marker determined in RTRT. Each con-
tinuous recording is one session. In each session, the maximumminus the minimum
is the difference in the LR, CC, and AP directions. b. Example of the RTRT amplitude
of one patient. (1) Session amplitude, (2) the maximum amplitude of the day, (3)
the mean amplitude of the day, (4) the maximum amplitude of the patient during
SBRT (Ampmax), (5) the mean amplitude of the patient during SBRT (Ampmean).
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those with 3DSA less than 10 mm in the LR direction (<10 mm
0.9 ± 1.7, 10 mm 6.0 ± 1.7, P = 0.01). No other statistical differences
were observed.
Relationships between the several clinical characteristics and the
mean difference between the AmpCT and the mean of the Ampmax
were investigated using ANOVA. Estimated percentages of total vari-
ance components using the REML method were determined as
shown in Table 2. For age, FEV1.0, lobe, and 3DSA, it was 0.0%, 4.4%,
5.1%, and 24.0%, respectively, in the LR direction; 0.0%, 1.1%, 29.7%,
and 0.0% in the CC direction; and 0.0%, 0.0%, 21.3%, and 5.5% in the
AP direction. These percentages suggest that the lobe and the 3DSA
contribute to the mean difference in the LR, CC, and AP directions
(Table 2). However, the residual component other than these clin-
ical characteristics in the variance is still large in all three directions.
Discussion
As a simple approach to generate individualized ITVs from 4DCT,
Ezhil et al. have investigated the accuracy of MIP-based ITV com-
pared with the method of contouring on all 10 phases [14]. Here
it was found that the MIP-based ITV underestimated the volume
Figure 3. a. Plots of the mean of the Ampmean and the mean of the AmpCT. (a) The mean of the Ampmean and (b) the mean of the AmpCT in the LR, CC, and AP directions.
b. Plots of the mean of the Ampmax and the mean of the AmpCT. (a) The mean of the Ampmax and (b) the mean of the AmpCT in the LR, CC, and AP directions.
Figure 4. The mean differences of the AmpCT from the Ampmax. (I) In the upper-
middle lobe and (II) in the lower lobe for the LR, CC, and AP directions.
Figure 5. The positions of each marker and its corresponding difference between the Ampmax and the AmpCT. On the frontal chest image (left panel), the vertical and hor-
izontal bars indicate the degrees of the differences expressed by ‘the Ampmax minus the AmpCT’ in the CC and LR directions, respectively. On the lateral chest image (right
panel), the vertical and horizontal bars indicate the degrees of the differences in the CC and AP directions, respectively. Green lines represent plus values and red lines rep-
resent minus values of the differences. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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in stage I and stage III NSCLC patients. It was further pointed out
that the MIP images may not fully display mobile structures if the
adjacent structures have similar densities, which is the case for
lesions located near the mediastinum, diaphragm, liver, and chest
wall. Mancosu et al. have proposed a semiautomatic technique for
deﬁning the internal margins of lung tumors close to the liver cupola
by 4DCT to overcome measurement errors due to the limitations
of MIP images [15]. In the present study, there are possible mea-
surement errors by metal marker artifacts on the 4DCT MIP images.
However, since the CT image number is much higher than that of
the surrounding tissue, we considered that any ambiguity in the
motion measurements was less than in the measurements of the
tumor mass which is composed of soft tissue and would present
the possibility of partial volume effects at the edge of the tumor.
The present study showed that the mean of the Ampmean was not
statistically different from the mean of the AmpCT in all three of the
LP, CC, and AP directions. This allows the conclusion that, as long
as the object is to determine the Ampmean it is suﬃcient and ac-
ceptable to use the AmpCT.
At the same time, the present study also showed that the mean
of the Ampmax was statistically signiﬁcantly larger than themean of
the AmpCT in all of the LP, CC, and AP directions. This is consistent
with previous suggestions of possible underestimation of the
maximum amplitudes measured with 4DCT MIP images [9]. The
reason why AmpCT is underestimated may be because the recon-
structed 4DCTMIP images are vulnerable to variations in respiratory
motionand todifferencesbetween internal respiratorymotion [16,17]
as well as to the motion of the skin surface marker used in 4DCT.
The longer time period for the delivery of SBRT compared to the
time needed for the 4DCT may also be a cause. Baseline drift of the
respiratorymotion and changes in the depth of respirationmay occur
during the longer period of the SBRT [18]. Remaining and new chal-
lenges of radiotherapy of 4D imaging have been reported previously
[19].
The mean difference between the AmpCT and the mean of the
Ampmax was larger in the lower lobe. This may be because of an in-
accurate reconstruction due to higher speed of motion of the tumor
in the lower lobe [11]. It is reasonable to expect that the smaller
motion in the upper and middle lobes resulted in the smaller
differences in the amplitudes of the upper and middle lobes. These
results do not disagree with previous results of differences in the
three-dimensional trajectory of skin surface and internal ﬁducial
markers either [20].
In general, previous reports have suggested that 4DCT can be ex-
pected to be useful especially for the lower lobe where the tumor
motion is large. However, the present study showed that the dif-
ference is signiﬁcantly larger in the lower lobe. This result stresses
that it is not safe to reduce the internal margin for tumors in the
lower lobe by using an ITV solely based on the 4DCT MIP. The mag-
nitude of the difference reached 12.5 ± 16.7 mm in the CC direction,
leading us to suggest that it cannot be recommended to use 4DCT
to estimate the internal margin for tumors in the lower lobe in
general. For tumors in the upper and middle lobes, Onodera et al.
have reported that an insigniﬁcant proportion of these tumors have
large amplitudes in patients with poor pulmonary function and in
patients who have a history of surgical operations of the thorax [21].
Based on these results, 4DCT may be considered adequate to esti-
mate the internal margins for tumors at the upper andmiddle lobes
in patients with normal pulmonary function.
In dynamic tracking of radiation therapy with real-time moni-
toring, the margins added to the clinical target volume (CTV) can
in principle be kept smaller than those determined for SBRT in free-
breathing [22–24]. However, our results suggest that extreme caution
must be paid not to miss-estimate the CTV when the external skin
surface or surrogate signals are used during the dynamic tracking
of a tumor based on the 4DCT data. Similarly, the most careful at-
tention should be paid to passive scattering particle therapy and
even more caution shown with intensity modulated radiotherapy
and spot scanning particle therapy where interplay effects of beam
and organ motion may deteriorate the dose distribution further.
It could be possible to improve the accuracy of the 4DCT by in-
creasing the time period where images are taken but this would
result in additional X-ray exposure. Also the difference in the re-
spiratory pattern at the treatment planning and at the actual
treatment will not be overcome by increasing the time for the 4DCT.
This study found that 3DSA and the position of the lobe contrib-
uted to the variation in the difference between treatment
planning and the actual treatment patterns. However, the residual
Table 1
Difference of the AmpCT from the mean of the Ampmax (Mean ± Standard Deviation).
Age FEV1.0 Lobe 3DSA
<77
(n = 11)
78≤
(n = 11)
P <1.8 L
(n = 11)
1.8 L≤
(n = 11)
P Upper-middle
(n = 11)
Lower
(n = 11)
P <10 mm
(n = 11)
10 mm≤
(n = 11)
P
LR (mm) 3.1 ± 3.7 3.9 ± 7.9 0.51 4.6 ± 8.2 2.4 ± 2.4 0.74 1.3 ± 1.1 5.7 ± 8.0 0.15 0.9 ± 1.7 6.0 ± 1.7 0.010*
CC (mm) 5.0 ± 8.0 8.1 ± 17.3 0.43 5.2 ± 12.1 7.9 ± 14.8 0.65 0.6 ± 3.1 12.5 ± 16.7 0.049* 4.0 ± 11.9 9.1 ± 14.6 0.17
AP (mm) 3.7 ± 4.8 4.3 ± 8.3 0.36 5.4 ± 8.7 2.5 ± 3.5 1.0 1.1 ± 1.7 6.8 ± 8.5 0.21 1.7 ± 4.6 6.2 ± 7.8 0.10
Abbreviations: LR = left-right, CC = cranial-caudal, AP = anterior-posterior, FEV1.0 = forced expiratory volume in 1 second, 3DSA = three-dimensional scalar amplitude. The
asterisk in Table 1 shows the statistical signiﬁcance (P < 0.05).
Table 2
Variance components for the mean of the AmpCT around the mean of the Ampmax.
LR CC AP
Variance (mm2) 95% CI (mm2) %* Variance (mm2) 95% CI (mm2) %* Variance (mm2) 95% CI (mm2) %*
Age 0 0 0.0 0 0 0.0 0 0 0.0
FEV1.0 1.9 0.2–8.7 4.4 2.3 0.6–4.0 1.1 0 0 0.0
Lobe 2.2 0.2–3.0 5.1 61.4 9.9–3,106,996.7 29.7 10.5 1.6–2,857,152.6 21.3
3DSA 10.3 1.5–8,265,330.5 24.0 0 0 0.0 2.7 0.3–1.8 5.5
Residual 28.5 16.3–61.9 66.5 143.4 82.3–310.4 69.2 36.2 21.0–76.6 73.2
Total 42.9 100.0 207.1 100.0 49.4 100.0
Abbreviations: LR = left-right, CC = cranial-caudal, AP = anterior-posterior, CI = conﬁdence interval, FEV1.0 = forced expiratory volume in 1 second, 3DSA = three-
dimensional scalar amplitude.
* Contribution of clinical characteristics to the total variance was shown as the percentage.
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component of variance was too large to be able to conﬁdently predict
the difference by using the clinical characteristics identiﬁed before
the treatment. The large residual component is probably reﬂect-
ing randomness in the respiratory motion and would be diﬃcult
to reduce by adding further clinical characteristics in the analysis.
Gated radiotherapy using the RTRT system has been suggested
to be useful to reduce the amount of residual error both for lung
as well as for abdominal tumors because of the real-time monitor-
ing of the tumor position [25]. The safety and eﬃcacy of RTRT for
treatment of stage I NSCLC has also been reported [13]. However,
caution must also be paid to possible dislocation of the ﬁducial
marker during the actual treatment (making its position different
from that at treatment planning) adding additional differences
between themotion of a tumor and themotion of the ﬁducial marker
near the tumor [26,27]. Jang et al. reported the importance of setting
an appropriate gaiting window regarding tumor characteristics as
necessary in gated SBRT in general for lung cancer [28].
The limitations of the present study relate to these problems of
gated SBRT using an RTRT system and ﬁducial markers. The rela-
tionship between the tumor motion and that of the ﬁducial marker
motion may change during the treatment. Ueki et al. reported that
the root mean squares of the standard deviations for each phase
were 0.6, 0.9, and 1.5 mm in the right-left, anterior-posterior, and
superior-inferior directions, respectively [29]. Therefore, since this
study is dealing with the discrepancies between the 4DCT and RTRT
for ﬁducial markers, the results should be interpreted with caution.
When applying the present results for general purposes, the pos-
sible discrepancy between the tumor itself and the ﬁducial markers
must be considered. Further investigation will be required to more
accurately detect real-time three-dimensional motion of the CTV
during the delivery of the irradiation.
Conclusion
The present study found that determining the amplitude mea-
sured with 4DCT MIP before SBRT treatment is adequate to know
the mean amplitude for a patient prior to SBRT. However, the study
also found that amplitudes measured with 4DCT MIP underesti-
mate the maximum amplitude of tumors at the lower lobe. This
stresses that great care must be paid to determine the margin of
organmotion accurately with 4DCT especially for tumors at the lower
lobe when the beneﬁts of the SBRT here are especially critical.
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